Trackinsight Enterprise, a unified platform for institutional ETF research, analytics, and compliance, is now live. Explore Trackinsight Enterprise →
Help us improve your experience. Please confirm your investor type:
Don’t Miss a Move in the ETF Market
Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.
ETFs with exposure to Corvus Pharmaceuticals, Inc. (CRVS)
F/m Emerald Life Sciences Innovation ETF - USD This ETF provides exposure to Other Mid and Small-Cap Equities | 2.06% | +17.63% | +24.06% | +€1M | +€5.3M | €108M | 0.79% | Not rated |
|---|---|---|---|---|---|---|---|---|
Virtus LifeSci Biotech Clinical Trials ETF - USD This ETF provides exposure to Equally Weighted US Equities | 1.19% | +17.61% | +33.41% | +€475K | +€6.2M | €45M | 0.65% | |
0.79% | +9.80% | +17.42% | -€667K | +€40M | €166M | 0.99% | Not rated | |
0.78% | +14.66% | +28.57% | +€10M | +€22M | €171M | 0.47% | ||
iShares Genomics Immunology and Healthcare Index ETF - CAD This ETF provides exposure to Equities | 0.78% | +18.01% | +33.44% | €0 | +€690K | €5.4M | 0.44% | |
Samsung KODEX SYNTH-US Biotech ETF - KRW This ETF provides exposure to Equally Weighted US Biotechnology Equities | 0.36% | +19.61% | +37.30% | €0 | -€69K | €16M | 0.25% | Not rated |
Global X S&P Biotech ETF - AUD This ETF provides exposure to Equally Weighted US Biotechnology Equities | 0.36% | +21.23% | +23.84% | +€925K | +€212K | €31M | 0.45% | Not rated |
State Street SPDR S&P Biotech ETF - USD This ETF provides exposure to Equally Weighted US Biotechnology Equities | 0.35% | +17.25% | +28.43% | +€768M | +€464M | €9.3B | 0.35% | |
0.14% | +4.95% | +27.47% | +€3.6M | +€100M | €1.34B | 0.6% | ||
0.14% | +4.40% | +33.98% | -€848K | +€4.8M | €244M | 0.25% | Not rated | |
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
Privacy policy | Cookie policy | | Terms of use | Imprint
